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Background: The Japanese Osteoporosis Quality of Life (JOQOL) questionnaire measures quality of life in Japanese
patients with osteoporosis. However, several important aspects of the psychometric properties of individual domains,
including responsiveness, have not been addressed to enable valid clinical application. This analysis examined the
internal and external responsiveness of the JOQOL questionnaire.
Methods: This was a post hoc analysis of a 24-week prospective postmarketing study of raloxifene (60 mg/day)
administered to postmenopausal Japanese women with osteoporosis (JapicCTI-070465). Internal responsiveness was
assessed using Standardized Response Mean (SRM) statistics and changes in JOQOL domain scores. Patients were also
stratified into those who did or did not achieve a minimal clinically important change (MCIC) in pain, assessed by a
visual analogue scale for pain (VAS pain): comparisons were made between treated patients who achieved VAS pain
reduction ≥ 20 mm versus VAS pain reduction < 20 mm. External responsiveness was assessed using Pearson ? s
correlation coefficient (r) for changes in JOQOL domain scores with Short Form-8 Health Survey and European Quality
of Life Instrument scores.
Results: Of 506 patients analyzed, 421 had a baseline value for VAS pain; of these, 152 patients (36.1%) had a MCIC,
whereas 264 patients (62.7%) did not. The JOQOL domains pain, overall health, and falls/psychological factors had small
to moderate SRM values (0.3-0.5) in all patients, but consistently showed significantly larger changes in patients whose
pain score changes exceeded the MCIC. Together, these findings suggest some degree of internal responsiveness for
these domains. However, activities of daily living domain had a SRM value as low as 0.2, and recreation/social activities
and posture/physique domains had SRM values close to 0. Moderate correlation (defined as r ≥ 0.4 to < 0.6) was noted
between the domains pain, activities of daily living, and overall health and some Short Form-8 Health Survey subscales
and the European Quality of Life total score, suggesting external responsiveness of these domains.
Conclusions: The inconsistent responsiveness among individual JOQOL domains in treated patients suggests the
need for improving several JOQOL domains, especially the activities of daily living, recreation/social activities and
posture/physique domains, before application to clinical research.
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Osteoporosis negatively affects quality of life (QOL) as
well as clinical and laboratory indices, such as fractures
and bone mineral density [1]. Improvement in QOL is
therefore an important endpoint for assessing the effect-
iveness of osteoporosis treatment from patients ? perspec-
tives. Reduced QOL in patients with osteoporosis is
primarily caused by fractures, particularly of the spine or
hip, which cause pain and impair physical function,
social function, and well-being [2-4].
The Japanese Osteoporosis Quality of Life (JOQOL)
questionnaire was developed to measure QOL in Japanese
patients with osteoporosis, with reference to two English
language disease-specific QOL questionnaires: the Qua-
leffo-41 questionnaire and the Osteoporosis Assessment
Questionnaire [3,5-7]. The current JOQOL evaluates the
health-related QOL of Japanese patients with osteoporosis
using 38 question items grouped into six domains (pain,
activities of daily living, recreation/social activities, overall
health, posture/physique, and falls/psychological factors).
Since its initial development, the JOQOL has been used
in a relatively small number of clinical studies [8-10].
The use of the JOQOL in these studies is based on an
early validation study that reported high reliability and
moderate correlation of the JOQOL total score with the
Medical Outcomes Study 36-Item Short-Form Health
Survey (SF-36) [7].
Patient-reported outcome (PRO) measures can pro-
vide evidence of a treatment benefit from patients ?
perspectives [11]. However, for such data to be meaning-
ful, it is necessary that the PRO instrument effectively
measures the concept under investigation. Further, before
application to clinical trials evaluating treatment effects,
the PRO must fulfill appropriate psychometric properties,
such as reliability, validity, the ability to detect change
in a measure (responsiveness), and interpretability (eg,
minimal clinically important change). Construct validity
is the ability of an instrument to accurately measure the
construct it was designed for [11,12], defined as how ? a
new instrument relates to other tests or measures in the
way one would expect if it is really measuring what it is
supposed to measure ? [13]. Responsiveness is one im-
portant aspect of construct validity, especially for esti-
mating the true treatment effect. Responsiveness is
determined by assessing the relationship between changes
in established endpoints and those of the PRO measure
over time [14].
Kumamoto et al. investigated part of the psychometric
properties of the overall JOQOL (total score), including
several aspects of reliability and validity [15]. However,
they did not examine the validity or reliability of the in-
dividual JOQOL domains. In addition, information about
other psychometric properties, including responsiveness,
was lacking. Because the JOQOL comprises multiple,discrete constructs, further validation of the JOQOL,
especially by domain, is warranted before its practical
application to clinical studies.
We previously reported significant improvement in
impaired QOL in postmenopausal women receiving
raloxifene using two established generic QOL instru-
ments: the Short Form-8 Health Survey (SF-8), and
the European Quality of Life Instrument (EQ-5D), as
well as a visual analogue scale for pain (VAS pain) and the
JOQOL questionnaire in a postmarketing study [16].
The aim of the present study was to examine the psy-
chometric properties of the JOQOL questionnaire in
this raloxifene-treated population with specific focus




This post hoc analysis examined the psychometric
properties of the JOQOL using data from a previous
postmarketing study. The 24-week prospective postmarket-
ing study of raloxifene administered in a real-world clinical
practice setting was conducted between 1 September
2007 and 28 February 2009 at 60 hospitals in Japan
(Japan Pharmaceutical Information Center registration
number JapicCTI-070465) [16].
The postmarketing study population and inclusion/
exclusion criteria have been reported previously [16].
The 24-week observation period for the postmarketing
study was based on a preceding prospective observational
study in postmenopausal women, in which the greatest
decrease in diffuse pain (considered to be caused by high
bone turnover [17]) was observed at 24 weeks [18]. Fur-
ther, in the postmarketing study, statistically significant
improvements were observed in all QOL instruments
(SF8, EQ-5D, and VAS pain) after 8 and 24 weeks of ralox-
ifene treatment [16]. Therefore, we considered it appropri-
ate to conduct this post hoc analysis using the 24-week
data of the postmarketing study. The primary objective of
the postmarketing study was to assess QOL during the ad-
ministration of raloxifene (60 mg daily; Evista?, Eli Lilly
and Company, Indianapolis, USA) using the SF-8, the EQ-
5D, two pain scales including VAS-pain, and the JOQOL.
The SF-8 was used for the power calculation and chosen
as the primary endpoint for the postmarketing study as it
is known to be equivalent to the SF-36 [19] while reducing
the burden for patients as it can be completed in one to
two minutes.
The postmarketing study was approved by the Institu-
tional Review Board of each participating hospital and
conducted in accordance with the Declaration of Helsinki
and all applicable local laws and regulations. Informed
consent was obtained from the study patients.
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Pain
Pain is the major symptomatic complaint in patients with
osteoporosis [2]. Pain intensity is a quantitative estimate
of the severity of perceived pain and is most commonly
assessed using VAS pain [20]. Therefore, in osteoporosis
research, VAS pain can represent a subjective measure for
patients? global assessment of changes in health status in
relation to the treatment effects of osteoporosis drugs. In
fact, pain intensity measured by a VAS was shown to be
significantly alleviated during raloxifene treatment in the
postmarketing study [16]. Before starting the postmar-
keting study, a VAS pain reduction ≥ 20 mm was chosen
preliminarily to represent a minimal clinically import-
ant change (MCIC) from the patients ? perspective [20].
Patients were stratified into two groups: (i) patients
achieving the MCIC (VAS pain reduction ≥ 20 mm) and
(ii) patients not achieving the MCIC (VAS pain reduc-
tion < 20 mm).
Responsiveness
Responsiveness was assessed using two different ap-
proaches. Internal responsiveness is the ability of a PRO
measure to change over the observation period when
treatment-related changes in health status are ? estab-
lished ? and is assessed using a distribution-based index
such as effect size [14,21]. Our previous report of this
study showed that significant improvement was seen in
back pain, joint pain, and diffuse bone pain after 8 weeks
of raloxifene treatment in the entire treatment group
and was greatest at 24 weeks. The other generic QOL
instruments, including SF-8 and EQ-5D, showed signifi-
cant improvements from the baseline values at the
8 weeks of raloxifene treatment and were again greatest
at the 24 weeks [16]. Therefore, in the present analysis
we used (i) Standardized Response Mean (SRM) values
to assess internal responsiveness [21] of the individual
JOQOL domains and (ii) changes in JOQOL domain
scores over 24 weeks (last observation carried forward;
LOCF). Changes in patients were compared between
subgroups stratified according to the MCIC [22]. This
was done to see whether each domain of the QOL in-
struments would be responsive in patients with a VAS
pain reduction ≥ 20 mm but not in patients with a VAS
pain reduction < 20 mm during osteoporosis treatment
[16]. External responsiveness is the extent to which
changes in a measure under investigation correlate with
changes in a validated ( ? external ? ) reference measure,
such as an established QOL instrument [21]. External
responsiveness is assessed by anchor-based methods that
use appropriate external criteria as ? anchors ? [14]. These
external criteria may be clinical endpoints, patient-rated
global improvement measures, or other PROs with
established responsiveness. A meaningful change in anestablished PRO measure that correlates with a change
in the PRO measure under investigation suggests that
the change in the investigation measure is also meaning-
ful [23]. External responsiveness of JOQOL domains
were verified against two external anchors: the SF-8
(subscale and summary scores) and the EQ-5D (total
score) via correlation analysis. As statistically significant
changes were observed in all SF-8 domain scores and
EQ-5D score for the whole group in the postmarketing
study [16], the SF-8 can be considered a responsive
measurement in this population.
Statistical analyses
Summary statistics for patient characteristics and the
JOQOL scores were determined as mean ? standard de-
viation (SD). For internal responsiveness assessment,
changes in JOQOL domain scores over the observation
period were compared between patients stratified by
MCIC and assessed using the Student t-test with a two-
sided alpha level of 0.05. The SRM is the mean of the dif-
ference of the change in JOQOL domain scores divided by
the SD of the difference; SRM values of ≥ 0.2 to < 0.5, ≥
0.5 to < 0.8, and ≥ 0.8 represented small, moderate, and
large internal responsiveness, respectively [21]. For exter-
nal responsiveness, Pearson? s correlation coefficients (r)
were calculated for changes in JOQOL domains and
changes in the external anchors [21]. Correlation coeffi-
cients of < 0.4, ≥ 0.4 to < 0.6, and ≥ 0.6 to < 0.8 represented
weak, moderate, and strong correlation, respectively [24].
Statistical analyses were conducted using SAS Version
9.1.3 (SAS Institute, Cary, NC, USA).
Results
Patient disposition and baseline characteristics
Of the 536 patients enrolled in the postmarketing study,
506 were eligible for analysis (30 patients excluded; 26
patients did not complete at least one follow-up visit, 1
patient violated concomitant drug protocol, 3 patients
had no case report form) [16]. In brief, patients were
postmenopausal women aged between 45 and 99 years.
The mean time since menopause was 21.4 years and the
mean period of treatment was 163.5 days (Table 1).
Pain
For the entire treatment group, VAS pain was reduced by
11.7 ? 25.8 mm (n = 416) from a baseline value of 40.2 ?
24.9 mm (n = 421), which corresponded to a moderate
SRM value of 0.45. Stratification of patients according to
the MCIC criteria showed that 152/421 patients (36.1%)
had a VAS pain reduction ≥ 20 mm (ie, achieved the
MCIC). These patients had a baseline mean ? SD VAS
pain score of 58.4 ? 16.8 mm, a mean ? SD reduction in
VAS pain of 38.7 ? 16.2 mm. In contrast, 264/421 patients
(62.7%) had a VAS pain reduction < 20 mm (ie, did not
Table 1 Patient characteristics
Characteristic n Mean (SD)
Age, years 506 70.7 (8.7)
Height, cm 419 150.2 (6.6)
Maximum height at adulthood, cm 156 153.1 (5.4)
Weight, kg 417 50.8 (8.4)
Body mass index, kg/m2 411 22.6 (3.5)
Years since menopause, years 217 21.4 (9.5)
Treatment period, days 506 163.5 (53.3)
Abbreviation: SD standard deviation.
Urushihara et al. Health and Quality of Life Outcomes 2014, 12:178 Page 4 of 8
http://www.hqlo.com/content/12/1/178achieve the MCIC). These patients had a mean ? SD base-
line VAS pain score of 30.0 ? 22.5 mm and a mean ? SD
change in VAS pain of -3.8 ? 15.3 mm, indicating no re-
duction in pain status and a significant difference with
those who achieved the MCIC (p < 0.001). These findings
confirmed that the predefined MCIC criteria differentiated
clearly between Japanese patients with osteoporosis who
experienced clinically significant changes in health status
related to perceived pain and those without such per-
ceived changes in pain.
Internal responsiveness of the JOQOL
The mean evaluation period for the different domains of
the JOQOL was consistent and ranged between 172.3 ?
11.4 days (range 117 to 196 days) and 174.3 ? 12.0 days
(range 120 to 196 days). For the entire treatment group,
the JOQOL domains including pain, activities of daily
living, overall health, and falls/psychological factors and
the total score showed small responsiveness with regard
to SRM values (0.4, 0.2, 0.5, 0.3, and 0.4, respectively;
Table 2). However, no responsiveness was observed for
the domains of recreation/social activities and posture/
physique for the entire treatment group (0.0 and 0.1, re-
spectively). After the stratification, the JOQOL domains
pain, activities of daily living, overall health, and falls/
psychological factors, and the total score had signifi-
cantly larger changes for patients achieving the MCICTable 2 Baseline and change in scores and internal responsiv
with osteoporosis for the entire treatment group
Domain Baseline
n Mean (SD)
Pain 407 14.1 (4.6)
Activities of daily living 416 51.2 (12.8)
Recreation/social activities 404 9.0 (4.8)
Overall health 436 5.1 (2.1)
Posture/physique 405 10.5 (3.8)
Falls/psychological factors 423 12.0 (4.1)
Total score 343 66.9 (15.8)
Abbreviations: JOQOL Japanese Osteoporosis Quality of Life questionnaire, SD stand
*Change from baseline to last observation carried forward.compared with patients not achieving the MCIC (p <
0.001; Table 3). Taken together, the above results show
some degree of internal responsiveness for the domains
pain, overall health, falls/psychological factors, and the
total score, however, the SRM for activities of daily living
indicated low internal responsiveness. For two JOQOL
domains (recreation/social activities and posture/phys-
ique; Table 3), the SRM values were consistently < 0.2
and the differences in mean changes in scores between
groups stratified by the MCIC criteria for these domains
were not statistically significant. For the SF-8 subscales
and the EQ-5D, small but consistent responsiveness
(SRM values 0.3-0.4) were observed in the entire treat-
ment group (Additional file 1). In patients achieving the
MCIC, significantly larger changes was noted for all the
SF-8 subscales (p ≤ 0.001 for all subscales) and the EQ-
5D total score (p < 0.001) (Additional file 2).
External responsiveness of the JOQOL
Moderate correlation was noted for changes in the
JOQOL domains pain, activities of daily living, overall
health, and the total score with changes in the external
anchors (ie, the various SF-8 subscales and the EQ-5D
total score; Table 4). Specifically, there was moderate
correlation for the JOQOL domain activities of daily liv-
ing and the SF-8 subscale general health (r = 0.43), the
JOQOL domain overall health and the SF-8 subscale
general health (r = 0.43), and the JOQOL domain pain
and the SF-8 subscale role physical (r = 0.40). Moderate
correlation was also noted for the changes in the
JOQOL activities of daily living and changes in the SF-8
physical component summary score (r = 0.43) and the
EQ-5D total score (r = 0.52). Overall, weak correlation
was noted for changes in the JOQOL domains recre-
ation/social activities, posture/physique, and falls/psy-
chological factors with changes in any of the SF-8
subscales or the EQ-5D total score (r < 0.4 for all corre-
lations). Of note, the correlation values of each individ-
ual JOQOL domain with the changes in various SF-8eness of the JOQOL in postmenopausal Japanese women
Change in score and internal responsiveness at 24 weeks*
n Mean (SD) SRM
277 1.9 (4.4) 0.4
280 1.6 (8.7) 0.2
271 0.0 (4.2) 0.0
309 1.0 (2.2) 0.5
267 0.3 (2.7) 0.1
300 0.9 (3.3) 0.3
216 4.0 (11.5) 0.4
ard deviation, SRM standardized response mean.
Table 3 Baseline and change in scores of the JOQOL in postmenopausal Japanese women with osteoporosis stratified
by minimal clinically important change in VAS pain
MCIC
(VAS pain reduction)
Baseline Change in score at 24 weeks*
n Mean (SD) n Mean (SD) p value?
Pain ≥ 20 mm 145 12.3 (4.4) 109 4.1 (4.7) < 0.001
< 20 mm 248 14.9 (4.4) 163 0.3 (3.5)
Activities of daily living ≥ 20 mm 148 46.0 (13.4) 110 6.1 (9.3) < 0.001
< 20 mm 250 53.8 (11.8) 165 -1.3 (7.1)
Recreation/social activities ≥ 20 mm 143 8.2 (4.8) 104 0.4 (4.3) 0.215
< 20 mm 242 9.3 (4.8) 160 -0.2 (4.1)
Overall health ≥ 20 mm 152 4.7 (2.0) 118 1.7 (2.4) < 0.001
< 20 mm 264 5.4 (2.2) 183 0.6 (2.1)
Posture/physique ≥ 20 mm 146 9.8 (3.6) 109 0.6 (2.7) 0.219
< 20 mm 241 10.8 (3.9) 153 0.2 (2.7)
Falls/psychological factors ≥ 20 mm 151 11.3 (4.1) 116 1.8 (3.6) < 0.001
< 20 mm 254 12.4 (4.0) 177 0.2 (3.0)
Total score ≥ 20 mm 133 61.0 (15.7) 93 9.7 (12.2) < 0.001
< 20 mm 201 70.4 (14.8) 120 -0.3 (9.0)
Abbreviations: JOQOL Japanese Osteoporosis Quality of Life questionnaire, MCIC minimal clinically important change, SD standard deviation, SRM standardized
response mean, VAS visual analogue scale.
*Change from baseline to last observation carried forward; ? Determined by two-sample t-test.
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ation that a domain-specific correlation pattern that
reflected the discrete SF-8 constructs and the construct
of each JOQOL domain would be observed.
Discussion
To our knowledge, this is the first study to examine the
responsiveness of the JOQOL, a disease-specific QOL
questionnaire for Japanese women with osteoporosis.
Some of the JOQOL domains tested in the present ana-
lysis including pain, fall/psychological factors, and overall
health showed limited internal responsiveness, compar-
able to the established SF-8 subscales and EQ-5D.
However, the activities of daily living, recreation/socialTable 4 Correlation of changes in JOQOL scores with changes
JOQOL
Domain GH PF RP BP
Pain 0.35 0.32 0.40 0.36
Activities of daily living 0.43 0.38 0.41 0.38
Recreation/social activities 0.12 0.13 0.18 0.05
Overall health 0.43 0.22 0.30 0.32
Posture/physique 0.09 0.07 0.15 0.20
Falls/psychological factors 0.29 0.29 0.35 0.32
Total score 0.50 0.44 0.50 0.46
aIn postmenopausal women with osteoporosis (n = 212 to 299).
Abbreviations: BP bodily pain, EQ-5D European Quality of Life Instrument, GH general h
component summary, MH mental health, PCS physical component summary, PF physic
functioning, SF-8 Short Form-8 Health Survey, VT vitality.activities and posture/physique domains were found to
be less- or non-responsive in regard to internal respon-
siveness. These findings for JOQOL domain internal re-
sponsiveness were largely consistent with the results of
the external responsiveness analysis. Our results indi-
cate that there may be further room for scrutinizing
and improving the JOQOL, a disease-specific QOL in-
strument developed to measure the treatment effective-
ness of osteoporosis medications.
Certain JOQOL domain scores (pain, activities of daily
living, overall health, falls/psychological factors) and the
total score showed small internal responsiveness among
the treatment population. These were fairly consistent
with the significantly larger changes among patients within external QoL measures (SF-8 and EQ-5D)a
SF-8 EQ-5D
VT SF MH RE PCS MCS
0.34 0.33 0.38 0.35 0.38 0.33 0.39
0.34 0.42 0.35 0.42 0.43 0.34 0.52
0.15 0.26 0.20 0.28 0.08 0.27 0.11
0.39 0.27 0.31 0.27 0.32 0.30 0.36
0.13 0.20 0.22 0.18 0.11 0.21 0.05
0.25 0.31 0.35 0.29 0.32 0.28 0.30
0.42 0.53 0.55 0.59 0.48 0.52 0.51
ealth, JOQOL Japanese Osteoporosis Quality of Life questionnaire, MCS mental
al functioning, QoL quality of life, RE role emotional, RP role physical, SF social
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domains recreation/social activities and posture/physique
failed to show adequate internal responsiveness with re-
gard to the SRM values and between-group differences.
Assessment of external responsiveness also found mod-
erate correlation between the JOQOL domains pain, activ-
ities of daily living, overall health, and the total score and
various subscales of the SF-8 and the EQ-5D total score as
references. However, homogeneous, non-specific correl-
ation patterns for changes in individual JOQOL domains
were observed regardless of the constructs measured by
the SF-8 subscales. This non-specific correlation pattern
did not support the expectation that a domain-specific
correlation pattern between the SF-8 constructs and the
JOQOL domains would be observed [7].
The findings of this study partly support the validity of
several JOQOL domains in terms of responsiveness for
detecting changes over time in QOL and subjective symp-
toms in patients with osteoporosis. However, the finding
that the JOQOL domains recreation/social activities and
posture/physique failed to show sufficient internal or ex-
ternal responsiveness requires further investigation. Add-
itionally, the internal responsiveness index for activities of
daily living had an SRM value as low as 0.2. Insufficient
responsiveness may be because these domains were de-
signed to measure concepts that are not specifically re-
lated to subjective pain, although pain was previously
shown to change during the course of raloxifene treat-
ment and was assumed to represent an improvement in
patient global assessment [16]. Indeed, the JOQOL do-
mains recreation/social activities and posture/physique
showed very low correlation with the SF-8 bodily pain
subscale, suggesting these particular JOQOL domains are
unrelated to pain. An earlier study conducted in Japan
that investigated the change in QOL in osteoporosis pa-
tients with back pain over six months supports this find-
ing [25]. In the postmarketing study, however, raloxifene
treatment was associated with improvements in scores for
all SF-8 subscales and the EQ-5D [16]. Therefore, the
treatment effects observed in the postmarketing study
were considered to affect all aspects of health-related con-
structs covered by the generic QOL measures (SF-8 and
EQ-5D), rather than just pain [19,26,27]. Alternatively, it
is possible that a ceiling effect (skewed distribution around
the upper limit of the scale) may be responsible, [12] at
least in part, for the lack of responsiveness observed for
the JOQOL domains recreation/social activities and
posture/physique. However, this alternative explanation
seems unlikely because, for both domains, middle-range
scores were present at baseline, which suggests that there
was potential for a change in scores.
The internal responsiveness analysis found that pain re-
lief was not associated with improvement in the JOQOL
recreation/social activities domain. This is contrary to thefact that the SF-8 social functioning subscale, which is ex-
pected to have a similar construct to the JOQOL recre-
ation/social activities, responded significantly in treated
patients [16]. Further, the JOQOL recreation/social activ-
ities domain showed low correlation with the SF-8 social
functioning subscale. These findings suggest that the
JOQOL recreation/social activities domain may have a dif-
ferent construct from the ? established? SF-8 social func-
tioning construct as well as questionable construct validity
in terms of responsiveness as an osteoporosis-specific
measure.
Similarly, the JOQOL domain posture/physique also
appears to have inadequate construct validity as an
osteoporosis-specific measure based on its unresponsive-
ness to treatment. The JOQOL domain posture/phys-
ique comprises items related to supposedly incurable
symptoms, including shortening of height and hunched
back. Further, the lack of correlation of the posture/
physique domain with any of the SF-8 subscales/summary
score and EQ-5D total score suggests that this domain
was not sufficiently sensitive to any treatment-related
changes in health-related QOL from the patients ?
perspectives.
A low SRM value for activities of daily living, repre-
senting weak internal responsiveness, appears to be as-
cribed to a larger SD of the change score. On the
contrary, the between-group difference of this domain
stratified by the MCIC criteria was large and signifi-
cant, and moderate or better correlations with external
anchors such as the SF-8 general health, social func-
tioning, role emotional and role physical subscales, and
the EQ-5D score were noted in the external responsive-
ness analysis compared with other JOQOL domains.
This inconsistency warrants further investigation.
The conceptual framework of the JOQOL suggests
that the individual JOQOL domains should have corre-
lated in a domain-specific manner with the individual
SF-8 subscales [7]. That is, a domain-specific correlation
pattern for certain JOQOL domains and individual SF-8
subscales that measure the same construct would be ex-
pected so that SF-8 subscales with similar concepts
should be correlated (convergent validity), but SF-8 sub-
scales with divergent concepts should not be correlated
(discriminant validity) [12]. The weak specificity of cor-
relations observed implies suboptimal construct validity
of the JOQOL domains and the possible need to re-
examine the conceptual framework of the JOQOL. Fur-
ther improvement in the construct validity of each
JOQOL domain by reliability and/or factor analysis ap-
pears warranted before formal clinical application of
this instrument.
There are several notable strengths and limitations of
the present study. In terms of study strengths, the results
of internal and external responsiveness were consistent,
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a sample population that was sufficiently large to deter-
mine responsiveness to treatment effects with osteopor-
osis medications in a real-world setting. Although this
confers generalizability to postmenopausal women with
osteoporosis, our results can only apply to postmeno-
pausal women with osteoporosis in Japan. This is because
treatment responsiveness and MCIC can only be general-
ized to the population studied [14]. Hence, a separate val-
idation study looking at men with osteoporosis in Japan is
warranted in this regard. Finally, we relied primarily on
the pain-related changes to establish ? subjective global
changes? during raloxifene treatment in the assessment of
responsiveness as discussed above. Therefore, the other
aspects of QOL unrelated to pain may be insufficiently
considered in the assessment of the responsiveness of the
JOQOL domains.Conclusions
This is the first report of the validity of individual domains
of the JOQOL questionnaire among Japanese women with
osteoporosis for the purpose of measuring treatment ef-
fects. Pain, overall health, falls/psychological factors, and
total score of the JOQOL seem to have limited responsive-
ness to treatment changes. Activities of daily living, recre-
ation/social activities and posture/physique domains were
less responsive based on SRM values than generic QOL
measures, such as the SF-8 and EQ-5D. Construct validity
of the JOQOL domains also seems to be problematic be-
cause all the domains of the JOQOL were correlated with
all aspects of health-related QOL covered by SF-8 in an
non-specific manner, possibly indicating lack of conver-
gent and discriminant validity. Thus, improvements in the
JOQOL are suggested before application to clinical re-
search for osteoporosis. Specifically, scrutiny of the con-
structs and content (especially those related to activities of
daily living, recreation/social activities and posture/phys-
ique), and factor analysis of the question items comprising
these domains may be recommended.Additional files
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